Evidence map›Paper›PMID 33157924›Full record

ReviewMedicine2020

Visceral leishmaniasis in patients with lymphoma: Case reports and review of the literature.

Galith Kalmi, Marie-Dominique Vignon-Pennamen, Caroline Ram-Wolff, Maxime Battistella, Mathieu Lafaurie, Jean-David Bouaziz, Samia Hamane, Sophie Bernard, Stéphane Bretagne, Catherine Thiéblemont and 2 more

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. InhibitingPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Galith KalmiService de Dermatologie, APHP, Hôpital Saint Louis.
Marie-Dominique Vignon-PennamenLaboratoire de Pathologie.
Caroline Ram-WolffService de Dermatologie, APHP, Hôpital Saint Louis.
Maxime BattistellaINSERM U976.
Mathieu LafaurieDépartement des maladies infectieuses et tropicales.
Jean-David BouazizService de Dermatologie, APHP, Hôpital Saint Louis.
Samia HamaneLaboratoire de Parasitologie, APHP, Hôpital Saint Louis.
Sophie BernardUniversité de Paris.
Stéphane BretagneLaboratoire de Parasitologie, APHP, Hôpital Saint Louis.
Catherine ThiéblemontUniversité de Paris.
Martine BagotService de Dermatologie, APHP, Hôpital Saint Louis.
Adèle de MassonService de Dermatologie, APHP, Hôpital Saint Louis.
Université Paris Cité · FRHôpital Saint-Louis · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-HIV-related visceral leishmaniasis (VL) is becoming increasingly prevalent in nontropical countries because of the increasing number of patients with chronic diseases and the development of immune-modulating drugs. PATIENT CONCERNS: Case 1 is a 60-year-old male patient of Senegalese origin presented with weight loss, lymphadenopathy, anemia, and elevated lactate dehydrogenases. Case 2 is a 46-year-old male patient of Algerian origin, with a negative HIV serology presented with cutaneous lesions. DIAGNOSIS: Patient 1: The diagnosis of stage IV lymphocytic lymphoma (LL) was confirmed by an inguinal nodal biopsy in 2013. Patient 2: The diagnosis of T-cell lymphoma was made in 2003.

interventionsPatient 1 received 5 cycles of bendamustine and rituximab followed by a complete remission. Patient 2 was initially treated with >10 different treatments followed by 8 different chemotherapy regimens due to the disease progression. OUTCOMES: Patient 1: In 2017, after a follow-up of 4 years, the patient presented with fever, lymphadenopathy, splenomegaly, and pancytopenia in the setting of hemophagocytic syndrome. The initial diagnosis was a relapse of lymphoma and the patient was treated with ibrutinib. His status worsened, and Leishmania DNA was detected by polymerase chain reaction (PCR) on the blood and bone marrow aspirates. Ibrutinib was stopped. Amphotericin B treatment induced a complete clinical remission and clearance of Leishmania DNA from the blood.Patient 2: In 2017, after a follow-up of 14 years, the patient presented with fever, lymphadenopathy, hepatosplenomegaly, pancytopenia with hemophagocytic syndrome, and an increase in the tumor skin lesions. A skin biopsy was taken from the face and the patient. A careful reexamination of the skin biopsy revealed the presence of Leishmania bodies. He was treated with 40 mg/kg liposomal amphotericin B leading to a regression of the clinical symptoms and negativation of the blood PCR.

conclusionsThis case study shows that VL may be a diagnostic challenge in patients with lymphoma. Reactivation or primary infection should be considered in the differential diagnosis. The purpose of this study is to remind clinicians to think of VL in patients with systemic symptoms that could be misdiagnosed as a progression of the underlying lymphoma.

Indexed as

Diagnosis, DifferentialDisease ProgressionHumansLeishmaniasis, VisceralLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedRemission Induction

Identifiers

PMID33157924
PMCPMC7647553
OpenAlexW3097505889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.